Clovis In Pole Position To Be First PARP For Prostate Cancer

Clovis is looking a steal a march on its rival PARP inhibitors and hopes to be the first drug in the class to get approval for prostate cancer following strong data seen in the TRITON trial.

Triton
Rubraca performed well in TRITON2 trial • Source: Shutterstock

Clovis Oncology Inc.'s PARP inhibitor Rubraca is showing promise in prostate cancer, according to data released at this year’s ESMO conference, as the company hopes to steal a march on AstraZeneca PLC and Merck & Co. Inc.’s more established rival drug.

With the PARP inhibitor space in ovarian cancer becoming ever more competitive, and AstraZeneca's Lynparza (olaparib) increasingly dominating, data presented...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By 

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.